Match!
Emilie Mamessier
Aix-Marseille University
45Publications
20H-index
1,494Citations
Publications 45
Newest
#2Pascal Finetti (AMU: Aix-Marseille University)H-Index: 42
Last.François Bertucci (AMU: Aix-Marseille University)
view all 7 authors...
ABSTRACTAdrenocortical carcinomas (ACCs) are heterogeneous cancers associated with a very poor prognosis. The improvement of prognostic tools and systemic therapy are urgently needed. Targeting the...
#2Pascal FinettiH-Index: 42
Last.François BertucciH-Index: 53
view all 0 authors...
Triple negative breast cancer (TNBC) represent 15% of breast cancers. Histoclinical features and marketed prognostic gene expression signatures (GES) failed to identify good- and poor-prognosis patients. Tyrosine kinases (TK) represent potential prognostic and/or therapeutic targets for TNBC. We sought to define a prognostic TK GES in a large series of TNBC. mRNA expression and histoclinical data of 6379 early BCs were collected from 16 datasets. We searched for a TK-based GES associated with di...
#1Yuchen Guo (University of Montpellier)
#2Monica Gabola (University of Montpellier)
view all 21 authors...
To clarify the function of cyclin A2 in colon homeostasis and colorectal cancer (CRC) we generated mice deficient for cyclin A2 in colonic epithelial cells (CEC). Colons of those mice displayed architectural changes in the mucosa, and signs of inflammation as well as an increased proliferation of CEC associated with the appearance of low- and high-grade dysplasia. The main initial events triggering those alterations in cyclin A2 deficient CEC appear to be abnormal mitoses and DNA damage. Cyclin ...
#2Emilie MamessierH-Index: 20
Last.Renaud SabatierH-Index: 11
view all 7 authors...
Ovarian cancers (OvC) are frequent, with more than 22,000 new cases each year for 14,000 deaths in the United States. Except for patients with BRCA1 or BRCA2 mutations, diagnostic methods, prognostic tools, and therapeutic strategies have not much improved in the last two decades. High throughput tumor molecular analyses have identified important alterations involved in ovarian carcinoma growth and spreading. However, these data have not modified the clinical management of most of patients. More...
Pancreatic adenocarcinoma (PAC) is one of the most aggressive human cancers and new systemic therapies are urgently needed. Exportin-1 (XPO1), which is a member of the importin-β superfamily of karyopherins, is the major exporter of many tumor suppressor proteins that are involved in the progression of PAC. Promising pre-clinical data using XPO1 inhibitors have been reported in PAC, but very few data are available regarding XPO1 expression in clinical samples. Retrospectively, we analyzed XPO1 m...
#1D BirnbaumH-Index: 34
Last.Emilie MamessierH-Index: 20
view all 5 authors...
The association between pancreatic ductal adenocarcinoma (PDAC) location (head vs. Body/Tail (B/T)) and clinical outcome remains controversial. We collected clinicopathological and gene expression data from 249 resected PDAC samples from public data sets, and we compared data between 208 head and 41 B/T samples. The 2-year overall survival (OS) was better for the head than for the B/T PDACs (44 vs. 27%, p = 0.043), especially when comparing tumors with similar TNM classification (T3/4N0M0: 67% v...
#1François Bertucci (AMU: Aix-Marseille University)H-Index: 28
#2Pascal FinettiH-Index: 42
Last.Daniel BirnbaumH-Index: 78
view all 11 authors...
The immunologic constant of rejection (ICR) is a broad phenomenon of Th-1 immunity-mediated, tissue-specific destruction. We tested the prognostic value of a 20-gene ICR expression signature in 8766 early breast cancers. Thirty-three percent of tumours were ICR1, 29% ICR2, 23% ICR3, and 15% ICR4. In univariate analysis, ICR4 was associated with a 36% reduction in risk of metastatic relapse when compared with ICR1-3 (p = 2.30E–03). In multivariate analysis including notably the three major progno...
#1David Jérémie Birnbaum (AMU: Aix-Marseille University)H-Index: 6
#2François Bertucci (AMU: Aix-Marseille University)H-Index: 28
Last.Emilie Mamessier (AMU: Aix-Marseille University)H-Index: 20
view all 5 authors...
Abstract Clinico-pathological factors fail to consistently predict the outcome after pancreatic resection for pancreatic ductal adenocarcinoma (PDAC). PDACs show a high level of inter- and intra- tumor genetic heterogeneity. A molecular classification should help sort patients into less heterogeneous and more appropriate groups regarding the metastatic risk and the therapeutic response, with the consequences of better predicting evolution and better orienting the treatment. PDAC can be classifie...
#1David Jérémie Birnbaum (AMU: Aix-Marseille University)H-Index: 6
#2Pascal Finetti (AMU: Aix-Marseille University)H-Index: 42
Last.François Bertucci (AMU: Aix-Marseille University)H-Index: 28
view all 5 authors...
Four molecular classifications of pancreatic ductal adenocarcinoma (PDAC), biologically and clinically relevant and based on gene expression profiles, were established in the recent years, including the Collisson’s, Moffitt’s (“tumor” and “stroma” classifications), and Bailey’s classifications. The aim of this study was to validate the prognostic value of the Moffitt’s classifications and to compare the Collisson’s, Moffitt’s, and Bailey’s classifications in a large series of samples. We collect...
12345